Mayne Pharma Group Yönetim

Yönetim kriter kontrolleri 1/4

Mayne Pharma Group CEO'su Shawn O’Brien, Oct2022 tarihinde atandı, in görev süresi 2.08 yıldır. in toplam yıllık tazminatı A$ 2.06M olup, şirket hissesi ve opsiyonları dahil olmak üzere 46.5% maaş ve 53.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.075% ine doğrudan sahiptir ve bu hisseler € 158.09K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 2.7 yıldır.

Anahtar bilgiler

Shawn O’Brien

İcra Kurulu Başkanı

AU$2.1m

Toplam tazminat

CEO maaş yüzdesi	46.5%
CEO görev süresi	2.1yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	2.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Shawn O’Brien'un ücretlendirmesi Mayne Pharma Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$2m	AU$959k	-AU$169m
Mar 31 2024	n/a	n/a	-AU$221m
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Tazminat ve Piyasa: Shawn 'nin toplam tazminatı ($USD 1.34M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 846.96K ).

Tazminat ve Kazançlar: Shawn şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Shawn O’Brien (65 yo)

2.1yrs

Görev süresi

AU$2,062,194

Tazminat

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% € 158.1k
Aaron Gray	Chief Financial Officer	2.3yrs	AU$1.31m	0.064% € 134.2k
Kimberly Parker	Executive VP & General Counsel	2.8yrs	Veri yok	Veri yok
Brant Schofield	Executive Vice President of Corporate Development	3.8yrs	AU$1.29m	Veri yok
Erinn Nathaniel	Director of Global Human Resources	1.8yrs	Veri yok	Veri yok
Daniel Moore	Executive Vice President of Commercial	5.2yrs	Veri yok	Veri yok
Frank Casty	Executive VP & Global Chief Medical Officer	1.8yrs	Veri yok	Veri yok
Brenton Walter	Financial Controller	20.3yrs	Veri yok	Veri yok
Laura Loftus	Associate General Counsel & Company Secretary	4.7yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: HG6 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% € 158.1k
Frank Condella	Independent Non-Executive Chairman	6.5yrs	AU$305.40k	0.081% € 171.3k
Bruce Robinson	Independent Non-Executive Director	10.3yrs	AU$219.39k	0.039% € 82.5k
Patrick Blake	Independent Non-Executive Director	6.4yrs	AU$218.36k	0.027% € 57.4k
Ann Custin	Independent Non-Executive Director	2.7yrs	AU$235.16k	0.026% € 55.5k
Kathryn MacFarlane	Independent Non-Executive Director	2.8yrs	AU$215.84k	0.047% € 98.7k
Anne Lockwood	Independent Non Executive Director	less than a year	AU$117.49k	Veri yok
David Petrie	Non-Executive Director	2.2yrs	AU$217.86k	Veri yok

2.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HG6 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Mayne Pharma Group Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

High number of new directors

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş